Financial Partners Group (Kansas)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Financial Partners Group (Kansas)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Buy	2,560 +471	+23%	+$63.7K	0.04%	169
2026 Q1	$267K	Hold	2,089	–	–	0.03%	194
2025 Q4	$261K	Buy	+2,089	New	+$240K	0.03%	201
2025 Q1	–	Sell	-2,426	Closed	-$219K	–	198
2024 Q4	$219K	Sell	2,426 -2	-0.1%	-$194	0.03%	172
2024 Q3	$240K	Sell	2,428 -208	-8%	-$20.4K	0.04%	169
2024 Q2	$244K	Sell	2,636 -196	-7%	-$17.6K	0.04%	157
2024 Q1	$269K	Hold	2,832	–	–	0.04%	150
2023 Q4	$253K	Buy	+2,832	New	+$210K	0.05%	141
2023 Q3	–	Sell	-2,832	Closed	-$230K	–	175
2023 Q2	$230K	Sell	2,832 -586	-17%	-$49K	0.05%	141
2023 Q1	$260K	Hold	3,418	–	–	0.06%	135
2022 Q4	$292K	Sell	3,418 -592	-15%	-$47.9K	0.06%	127
2022 Q3	$318K	Sell	4,010 -273	-6%	-$23K	0.08%	110
2022 Q2	$318K	Sell	4,283 -220	-5%	-$16.5K	0.08%	107
2022 Q1	$405K	Sell	4,503 -572	-11%	-$52.8K	0.09%	113
2021 Q4	$474K	Sell	5,075 -188	-4%	-$22.7K	0.1%	102
2021 Q3	$662K	Sell	5,263 -50	-0.9%	-$6.44K	0.16%	79
2021 Q2	$719K	Sell	5,313 -312	-6%	-$41K	0.19%	65
2021 Q1	$763K	Sell	5,625 -152	-3%	-$22.8K	0.22%	58
2020 Q4	$871K	Buy	5,777 +1	+0%	+$128	0.26%	51
2020 Q3	$644K	Buy	5,776 +1	+0%	+$112	0.22%	49
2020 Q2	$646K	Buy	5,775 +1	+0%	+$98	0.25%	44
2020 Q1	$423K	Sell	5,774 -31	-0.5%	-$2.75K	0.26%	38
2019 Q4	$533K	Sell	5,805 -341	-6%	-$29.5K	0.21%	47
2019 Q3	$469K	Sell	6,146 -204	-3%	-$17K	0.21%	45
2019 Q2	$557K	Sell	6,350 -277	-4%	-$23.6K	0.26%	43
2019 Q1	$600K	Hold	6,627	–	–	0.32%	45
2018 Q4	$476K	Sell	6,627 -265	-4%	-$21.4K	0.31%	45
2018 Q3	$661K	Hold	6,892	–	–	0.43%	40
2018 Q2	$656K	Hold	6,892	–	–	0.48%	41
2018 Q1	$604K	Sell	6,892 -75	-1%	-$6.85K	0.47%	43
2017 Q4	$591K	Buy	+6,967	New	+$584K	0.47%	45

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Financial Partners Group (Kansas)'s XBI Position: Q2 2026 in Review

Financial Partners Group (Kansas) increased its State Street SPDR S&P Biotech ETF (XBI) stake by 23% in Q2 2026, buying an estimated $63.7K and bringing the position to 2,560 shares worth $405K. The position accounts for 0.04% of the portfolio, ranked #169.

Financial Partners Group (Kansas) first reported a position in XBI in Q4 2017 and has held it in 31 quarters since. The position peaked at $871K in Q4 2020. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Financial Partners Group (Kansas) held 2,560 shares of State Street SPDR S&P Biotech ETF worth $405K as of Q2 2026.
Financial Partners Group (Kansas) bought 471 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $63.7K.
State Street SPDR S&P Biotech ETF made up 0.04% of Financial Partners Group (Kansas)'s portfolio in Q2 2026, its #169 holding.
Financial Partners Group (Kansas) first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 31 quarters since.
Financial Partners Group (Kansas)'s State Street SPDR S&P Biotech ETF position peaked at $871K in Q4 2020.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Financial Partners Group (Kansas)'s 13F filing for Q2 2026, filed 23 Jul 2026.